Logo image of FEMY

FEMASYS INC (FEMY) Stock Fundamental Analysis

NASDAQ:FEMY - Nasdaq - US31447E1055 - Common Stock - Currency: USD

0.8651  -0.03 (-3.88%)

Fundamental Rating

2

FEMY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. FEMY has a bad profitability rating. Also its financial health evaluation is rather negative. FEMY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FEMY had negative earnings in the past year.
FEMY had a negative operating cash flow in the past year.
FEMY had negative earnings in each of the past 5 years.
In the past 5 years FEMY always reported negative operating cash flow.
FEMY Yearly Net Income VS EBIT VS OCF VS FCFFEMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -159.02%, FEMY is doing worse than 91.44% of the companies in the same industry.
With a Return On Equity value of -1057.44%, FEMY is not doing good in the industry: 90.37% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -159.02%
ROE -1057.44%
ROIC N/A
ROA(3y)-89.97%
ROA(5y)-77.42%
ROE(3y)-322.97%
ROE(5y)-238.66%
ROIC(3y)N/A
ROIC(5y)N/A
FEMY Yearly ROA, ROE, ROICFEMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

FEMY's Gross Margin of 66.24% is fine compared to the rest of the industry. FEMY outperforms 69.52% of its industry peers.
FEMY's Gross Margin has declined in the last couple of years.
FEMY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y-2.71%
FEMY Yearly Profit, Operating, Gross MarginsFEMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

0

2. Health

2.1 Basic Checks

FEMY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FEMY has been increased compared to 1 year ago.
FEMY has more shares outstanding than it did 5 years ago.
The debt/assets ratio for FEMY is higher compared to a year ago.
FEMY Yearly Shares OutstandingFEMY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FEMY Yearly Total Debt VS Total AssetsFEMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -17.13, we must say that FEMY is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FEMY (-17.13) is worse than 88.77% of its industry peers.
A Debt/Equity ratio of 2.89 is on the high side and indicates that FEMY has dependencies on debt financing.
FEMY has a Debt to Equity ratio of 2.89. This is amonst the worse of the industry: FEMY underperforms 88.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.89
Debt/FCF N/A
Altman-Z -17.13
ROIC/WACCN/A
WACC7.74%
FEMY Yearly LT Debt VS Equity VS FCFFEMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.93 indicates that FEMY may have some problems paying its short term obligations.
FEMY's Current ratio of 0.93 is on the low side compared to the rest of the industry. FEMY is outperformed by 91.44% of its industry peers.
FEMY has a Quick Ratio of 0.93. This is a bad value and indicates that FEMY is not financially healthy enough and could expect problems in meeting its short term obligations.
FEMY has a worse Quick ratio (0.54) than 92.51% of its industry peers.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.54
FEMY Yearly Current Assets VS Current LiabilitesFEMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

FEMY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.33%.
Looking at the last year, FEMY shows a very strong growth in Revenue. The Revenue has grown by 62.05%.
The Revenue has been growing by 11.86% on average over the past years. This is quite good.
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.29%
Revenue 1Y (TTM)62.05%
Revenue growth 3Y11.35%
Revenue growth 5Y11.86%
Sales Q2Q%25.86%

3.2 Future

FEMY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.13% yearly.
Based on estimates for the next years, FEMY will show a very strong growth in Revenue. The Revenue will grow by 117.00% on average per year.
EPS Next Y23.8%
EPS Next 2Y26.65%
EPS Next 3Y18.21%
EPS Next 5Y18.13%
Revenue Next Year128.46%
Revenue Next 2Y144.2%
Revenue Next 3Y145.11%
Revenue Next 5Y117.01%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FEMY Yearly Revenue VS EstimatesFEMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
FEMY Yearly EPS VS EstimatesFEMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FEMY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FEMY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FEMY Price Earnings VS Forward Price EarningsFEMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FEMY Per share dataFEMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

FEMY's earnings are expected to grow with 18.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.65%
EPS Next 3Y18.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FEMY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FEMASYS INC

NASDAQ:FEMY (7/28/2025, 4:19:14 PM)

0.8651

-0.03 (-3.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06
Inst Owners12.06%
Inst Owner Change-0.35%
Ins Owners10.57%
Ins Owner Change5.27%
Market Cap28.14M
Analysts82
Price Target7.4 (755.39%)
Short Float %0.73%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.28%
Min EPS beat(2)-21.89%
Max EPS beat(2)-18.68%
EPS beat(4)0
Avg EPS beat(4)-19.25%
Min EPS beat(4)-21.89%
Max EPS beat(4)-17.65%
EPS beat(8)2
Avg EPS beat(8)-9.65%
EPS beat(12)5
Avg EPS beat(12)-4.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-68.03%
Min Revenue beat(2)-70.71%
Max Revenue beat(2)-65.36%
Revenue beat(4)0
Avg Revenue beat(4)-56.25%
Min Revenue beat(4)-72.34%
Max Revenue beat(4)-16.58%
Revenue beat(8)1
Avg Revenue beat(8)-37.83%
Revenue beat(12)1
Avg Revenue beat(12)-30.36%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)-29.59%
Revenue NQ rev (1m)28.06%
Revenue NQ rev (3m)-43.6%
Revenue NY rev (1m)15.67%
Revenue NY rev (3m)-29.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.56
P/FCF N/A
P/OCF N/A
P/B 14.09
P/tB 14.52
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.05
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -159.02%
ROE -1057.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.24%
FCFM N/A
ROA(3y)-89.97%
ROA(5y)-77.42%
ROE(3y)-322.97%
ROE(5y)-238.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y-2.71%
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 2.89
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.92%
Cap/Sales 50.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.54
Altman-Z -17.13
F-Score4
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)62.1%
Cap/Depr(5y)48.65%
Cap/Sales(3y)33.12%
Cap/Sales(5y)25.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.29%
EPS Next Y23.8%
EPS Next 2Y26.65%
EPS Next 3Y18.21%
EPS Next 5Y18.13%
Revenue 1Y (TTM)62.05%
Revenue growth 3Y11.35%
Revenue growth 5Y11.86%
Sales Q2Q%25.86%
Revenue Next Year128.46%
Revenue Next 2Y144.2%
Revenue Next 3Y145.11%
Revenue Next 5Y117.01%
EBIT growth 1Y-32.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-87.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-84.77%
OCF growth 3YN/A
OCF growth 5YN/A